Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimethoprim-sulfamethoxazole for opportunistic infection prevention in lupus on low-level immunosuppression
TCTR20230606002Phase 3Completed
- Sponsor
- Mahidol University
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trimethoprim + sulfamethoxazole in opportunistic infection, systemic lupus erythematosus (SLE), sponsored by Mahidol University. Started Jul 2022; status: completed.
02
Drugs
trimethoprim + sulfamethoxazole
03
Conditions
opportunistic infectionsystemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on TCTR20230606002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230606002.